Corneal pannus (chronic superficial keratitis) in the German Shepherd Dog

Bedford, P. G. C.; Longstaffe, J. A.

doi:10.1111/j.1748-5827.1979.tb07019.x

Cited by 31 publications

(33 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pharmacological treatment of CSK is based on corticosteroids which can be administered as ophthalmic drops, ophthalmological ointment, or subconjunctival injections (Bedford 1979, Williams 1995, Clerk 1996, Balicki 2008. One of the most important medications in the treatment of CSK is cyclosporine, which can also be used in long-term therapy (Balicki 2005).…”

Section: Introductionmentioning

confidence: 99%

Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs

Balicki¹

2012

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

The objective of this study was to assess the treatment of chronic superficial keratitis (CSK) in dogs with the use of tacrolimus and DMSO.The study was conducted on 16 dogs -7 males and 9 females, aged 3 to 11 years, diagnosed with CSK. The disease was treated with ophthalmic drops containing 0.02% tacrolimus and 50% DMSO, administered to the ocular surface three times a day. Prior to the treatment and after 5 weeks of therapy, the corneal neovascularisation, pigmentation, and also the redness and depigmentation of the third eyelid margin were assessed. The percentage of the corneal surface afflicted with inflammatory processes was calculated on the basis of photographs taken with the use of IsoCalc.com's Get Area software for Corel DRAW 12.It was found that the application of tacrolimus and DMSO caused a reduction of inflammatory process and neovascularisation in the cornea. The mean corneal surface afflicted with inflammatory processes was statistically significantly reduced from 69.9% to 43.9% (p ≤ 0.01) -in case of the right corneas, and from 58.9% to 38.6% in case of the left corneas. Of 32 corneas diagnosed with the pigmentation, the reduction of the pigmentation was observed in 14, while in 16 the pigmentation increased.The treatment of CSK with the use of tacrolimus and DMSO causes the reduction in terms of inflammatory processes and neovascularisation, but in many cases does not inhibit the progress of the pigmentation.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs

Balicki¹

2012

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…The CSK disease occurs more often in males with almost identical frequency in both countries. In other studies (Bedford andLongstaffe 1979, Chavkin et al 1994) the most affected dogs were females. In these studies, 79.8% (Chavkin et al 1994) to 82% (Bedford and Longstaffe 1979) females had been spayed.…”

Section: Resultsmentioning

confidence: 78%

“…In other studies (Bedford andLongstaffe 1979, Chavkin et al 1994) the most affected dogs were females. In these studies, 79.8% (Chavkin et al 1994) to 82% (Bedford and Longstaffe 1979) females had been spayed. It could be the reason why the males in our study are the most affected, because all females were sexually intact, except 5 females in Poland.…”

Section: Resultsmentioning

confidence: 78%

See 1 more Smart Citation

A retrospective study of the occurrence of Chronic Superficial Keratitis in 308 German Shepherd dogs: 1999-2010

Drahovska

Balicki

Trbolová

et al. 2014

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Chronic Superficial Keratitis (CSK) is an autoimmune mediated inflammation of the cornea, that is usually bilateral but often with nonsymmetrical manifestation.The aim of this study was to determine the occurrence and appearance of clinical symptoms of CSK in German Shepherd dogs in Poland and Slovakia.CSK was diagnosed in 308 German Shepherds for a period of 11 years (from 1999 to 2010). The highest incidence of the CSK (p < 0.001) in Slovakia and in Poland was in dogs between the ages of 5-8 years. This study found similarity in gender ratio of affected patients with CSK in two neighboring countries. This disease occurs most often in males, with almost identical frequency in both countries, Slovakia 65.63% and Poland 61.32%, respectively. The incidence of depigmentation and thickening of the external surface of the third eyelid together with CSK was observed in 69.19% of dogs in Poland and in 63.15% of dogs in Slovakia. CSK is often recognized in advanced stage-affected areas with inflammatory process by CSK, obtained frequently from 2 to 3 quadrants.

show abstract

“…Auch ohne Keratektomie wird in therapieresistenten Fällen die Bestrahlung mit Betastrahlern empfohlen [1,15], klinisch kontrollierte Untersuchungen hierzu existieren jedoch ebenso wenig wie detaillierte Angaben zur Dosierung, Dosisspezifikation und zu den Nebenwirkungen.…”

Section: Introductionunclassified

Die Behandlung der Keratitis superficialis chronica des Hundes mit Strontium-90

Höcht

Gruning²,

Allgoewer³

et al. 2002

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

show abstract

Corneal pannus (chronic superficial keratitis) in the German Shepherd Dog

Abstract: The clinical features, histopathology and treatment of corneal pannus (chronic superficial keratitis) in a series of eighty‐four German Shepherd Dogs are reported. The aetiology of the condition and its therapeutic management are discussed in the light of these findings.

Cited by 31 publications

References 5 publications

Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs

Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs

A retrospective study of the occurrence of Chronic Superficial Keratitis in 308 German Shepherd dogs: 1999-2010

Die Behandlung der Keratitis superficialis chronica des Hundes mit Strontium-90

Contact Info

Product

Resources

About